Earnings Data
Report Date
Jul 28, 2026TBA (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
0.91Last Year’s EPS
0.84Same Quarter Last Year
Strong Buy
Based on 5 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call presented a constructive picture: solid organic growth, stronger adjusted profitability, improving free cash flow and early, measurable progress from a comprehensive transformation program with clear 2028 financial targets. These positives are tempered by sizeable one-off exceptional charges (largely non-cash impairments), near-term volatility in Pharma Solutions and Industrial Specialties, FX and inflationary pressures, and the prospect of further restructuring actions. On balance, management has credible plans and early execution momentum, but material one-off charges and some segment volatility keep performance recovery from being yet fully de-risked.Company Guidance
Top-line Growth
Sales grew 7% in constant currency to GBP 1.7bn for FY2025; Q4 sales up 5% CC. Growth was broad-based with Consumer Care +8% (Q4 +9%) and Life Sciences +8% (Q4 +8%).
Strong Performance in Patented Ingredients and NPS
Sales of patented ingredients increased 9% and Net Promoter Score improved by 11 points, indicating stronger customer trust, service and collaboration.
Improved Profitability (Adjusted)
Adjusted operating profit increased 8% to GBP 295m and adjusted profit before tax grew 8% to GBP 276m. EBITDA rose 5% to GBP 397m.
Free Cash Flow and Balance Sheet Strengthening
Free cash flow was GBP 162m in FY2025 (benefitting from lower CapEx and working capital in H2). Net debt reduced slightly to GBP 524m and leverage improved to 1.3x EBITDA (from 1.5x).
CapEx Discipline
Capital expenditure reduced from GBP 138m to GBP 108m, below prior guidance of GBP 135m (CapEx now targeted at around 6% of sales going forward).
Transformation Progress and Cost Savings
Transformation delivered GBP 28m of recurring savings in 2025. Management targets GBP 100m annualized savings by FY2028 and GBP 50m working capital reduction; remaining transformation benefits around GBP 75m to drive margin recovery.
Clear 2028 Financial Targets
Management set a three-year framework: group organic sales growth 3–6% pa, Life Sciences 4–7% and Consumer Care 3–6%; adjusted operating margin >20% by FY2028 (from 17.4% in 2025); free cash flow conversion target >12% and ROIC >10%.
High-growth Niches and Geographic Repositioning
Portfolio now has 89% of sales in consumer, pharma or agricultural markets (up from 73% in 2019). 48% of sales are outside Europe/North America (up from 37%) and several niche areas (F&F, plant stem cells, biologics) are growing faster than the market.
Notable Segment Wins
Fragrances & Flavors grew 15% FY2025 and Crop Protection grew 14% for the full year (Q4 Crop Protection +12%), with Seed Enhancement +8% and Beauty Actives +6%.
DE:6CMB Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
DE:6CMB Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Feb 24, 2026 | €33.19 | €35.15 | +5.90% |
Jul 29, 2025 | €31.59 | €30.14 | -4.57% |
Feb 25, 2025 | €35.95 | €36.27 | +0.89% |
Jul 30, 2024 | €44.36 | €44.80 | +1.00% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Croda International PLC (DE:6CMB) report earnings?
Croda International PLC (DE:6CMB) is schdueled to report earning on Jul 28, 2026, TBA (Confirmed).
What is Croda International PLC (DE:6CMB) earnings time?
Croda International PLC (DE:6CMB) earnings time is at Jul 28, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Croda International PLC stock?
The P/E ratio of Croda International is N/A.
What is DE:6CMB EPS forecast?
DE:6CMB EPS forecast for the fiscal quarter 2026 (Q2) is 0.91.